Lupin :

This is yet another GOOD STOCK for Tough Times. To know more about the reason why we chose this stock for this investing currently, Click Here:

- Started in 1968
- 5th largest generic player in US with market share of 5.1% by prescriptions as per IMS Health
- 3rd largest Indian Pharma company by sales.
- World's Largest Manufacturer of Tuberculosis durgs.
- Speciales in Cardiovascular, diabetology, asthma, pediatric, gstrointestinal, anti-infective, non-steroidal anti-inflamatory drungs.
- Files for 25 Abbreviated New Drugs (ANDAS) in 2012.
- Has five active pharma ingredients (API) and seven formulation plants - 2 of which are in Japan.
- Overseas market contributes 70% of Lupins Revenue.
- Revenue Share breakup: US:38%, Japan-12%
- In India - has 230 brand of which three have turnover in excess of Rs.50 Crores.
- Reported Compounded Annual Growth Rate (CAGR) of 25% Profit between FY2007-FY2012.
- Going forward - Plans to launch over 120 products in US Markets.